Leerink Partnrs Research Analysts Reduce Earnings Estimates for Bio-Techne Co. (NASDAQ:TECH)

Bio-Techne Co. (NASDAQ:TECH - Free Report) - Leerink Partnrs lowered their Q1 2025 EPS estimates for shares of Bio-Techne in a report issued on Wednesday, September 18th. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will post earnings per share of $0.34 for the quarter, down from their previous forecast of $0.36. The consensus estimate for Bio-Techne's current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for Bio-Techne's Q2 2025 earnings at $0.34 EPS, FY2025 earnings at $1.69 EPS, Q1 2026 earnings at $0.44 EPS, Q2 2026 earnings at $0.45 EPS and Q4 2026 earnings at $0.62 EPS.

Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.49. Bio-Techne had a return on equity of 12.88% and a net margin of 14.50%. The business had revenue of $306.10 million for the quarter, compared to analysts' expectations of $306.49 million. During the same quarter last year, the firm earned $0.56 earnings per share. The business's revenue was up 1.6% on a year-over-year basis.

Other equities analysts have also issued research reports about the stock. Robert W. Baird increased their price target on shares of Bio-Techne from $81.00 to $82.00 and gave the stock an "outperform" rating in a research note on Thursday, August 8th. Royal Bank of Canada dropped their price objective on Bio-Techne from $72.00 to $70.00 and set a "sector perform" rating for the company in a report on Thursday, August 8th. Citigroup cut Bio-Techne from a "buy" rating to a "neutral" rating and set a $85.00 target price on the stock. in a report on Wednesday, May 22nd. Finally, Benchmark restated a "buy" rating and set a $95.00 price target on shares of Bio-Techne in a research note on Tuesday, August 13th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, Bio-Techne has an average rating of "Moderate Buy" and a consensus target price of $80.60.

Bio-Techne Trading Up 5.0 %

Shares of NASDAQ TECH traded up $3.85 on Thursday, reaching $80.36. 1,534,011 shares of the company traded hands, compared to its average volume of 1,041,983. The stock has a market capitalization of $12.75 billion, a PE ratio of 64.17, a P/E/G ratio of 5.06 and a beta of 1.27. Bio-Techne has a fifty-two week low of $51.79 and a fifty-two week high of $85.57. The company has a current ratio of 3.87, a quick ratio of 2.75 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average of $75.15 and a 200 day moving average of $73.92.

Bio-Techne Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, August 30th. Investors of record on Monday, August 19th were issued a dividend of $0.08 per share. The ex-dividend date of this dividend was Monday, August 19th. This represents a $0.32 annualized dividend and a dividend yield of 0.40%. Bio-Techne's payout ratio is currently 25.40%.

Hedge Funds Weigh In On Bio-Techne

Institutional investors and hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of Bio-Techne by 92.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,746,119 shares of the biotechnology company's stock valued at $404,470,000 after purchasing an additional 2,755,065 shares during the period. Brown Capital Management LLC boosted its position in Bio-Techne by 12.4% in the 4th quarter. Brown Capital Management LLC now owns 3,550,990 shares of the biotechnology company's stock valued at $273,994,000 after buying an additional 392,986 shares during the last quarter. Mairs & Power Inc. boosted its position in Bio-Techne by 0.8% in the 4th quarter. Mairs & Power Inc. now owns 3,079,483 shares of the biotechnology company's stock valued at $237,613,000 after buying an additional 25,903 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Bio-Techne by 14.0% during the first quarter. Bank of New York Mellon Corp now owns 2,862,526 shares of the biotechnology company's stock valued at $201,493,000 after acquiring an additional 351,645 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in shares of Bio-Techne by 8.2% during the second quarter. Mackenzie Financial Corp now owns 2,862,260 shares of the biotechnology company's stock worth $205,081,000 after acquiring an additional 216,044 shares during the last quarter. Hedge funds and other institutional investors own 98.95% of the company's stock.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.